Most of the EU pharmaceutical reform will apply about two years after entry into force, but some provisions are expected to take effect immediately. Published analyses name regulatory sandboxes and the transferable exclusivity voucher among them.
Provisions expected on entry into force
Law firm summaries list the transferable data exclusivity voucher for priority antimicrobials, regulatory sandboxes, critical medicine supply provisions and certain EMA cooperation and funding measures as applying on entry into force, which is 20 days after Official Journal publication.
Regulatory sandboxes
A sandbox is a controlled environment in which regulators and developers can test novel approaches under supervision. Details will come from the legal text and guidance, but the concept is aimed at innovation that does not fit established pathways, for example new technologies or unusual manufacturing and data approaches.
The antimicrobial voucher
The voucher grants one additional year of data protection and is transferable. Published analyses mention a ceiling linked to annual gross sales of EUR 490 million. For developers of priority antimicrobials, it offers a tangible incentive, while for holders of other products it may become a tradable asset.
What to do now
- Monitor secondary acts. Eligibility criteria and procedures will be defined in detail later.
- Identify candidate projects. Innovative technologies or priority antimicrobials may benefit.
- Engage early. Informal discussions with regulators on novel approaches help shape how sandboxes work in practice.
How PQRA helps
PQRA helps innovators assess whether new pathways fit their programmes, prepares scientific advice requests and keeps clients informed on implementing acts and guidance.


No responses yet